Memantine Hydrochloride/Donepezil Hydrochloride

็›้…ธ็พŽ้‡‘ๅˆš/็›้…ธๅคšๅฅˆๅ“Œ้ฝ

Report date: 2023/02/22 16:45:06

Base Information

Drug NameMemantine Hydrochloride/Donepezil Hydrochloride
Drug Alias NameDonepezil Hydrochloride/Memantine Hydrochloride็›้…ธๅคšๅฅˆๅ“Œ้ฝ/็›้…ธ็พŽ้‡‘ๅˆšDonepezil/Memantineๅคšๅฅˆๅ“Œ้ฝ/็พŽ้‡‘ๅˆšArimenda +[12]ย 
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonistsAcetylcholinesterase inhibitors
TargetsGlutamate [NMDA] receptorAcetylcholinesterase
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsAlzheimer Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/12/23
Country/TerritoryUnited StatesSouth KoreaEU
CombinationsYes Donepezil HydrochlorideMemantine Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncHyundai Pharm. Co Ltd
Inactive CompaniesHyundai Pharmaceutical Co LtdMerz Pharmaceuticals GmbhH. Lundbeck A/S
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN06DA52
Related LinksN/A